医学
溶栓
闭塞
冲程(发动机)
随机对照试验
内科学
多元分析
心脏病学
单变量分析
前瞻性队列研究
外科
心肌梗塞
机械工程
工程类
作者
Valerio Da Ros,Jonathan Cortese,Olivier Chassin,Aymeric Rouchaud,Mariana Sarov,Jildaz Caroff,Cristian Mihalea,Silvia Minosse,Irina Taifas,Jacopo Scaggiante,Laura S. López Greco,Léon Ikka,Nidhal Ben Achour,Francesca Di Giuliano,Augustin Ozanne,Nicolas Legris,Marina Diomedi,Fabrizio Sallustio,Roberto Floris,Christian Denier,Laurent Spelle
标识
DOI:10.1016/j.neurad.2019.01.089
摘要
To compare outcomes of minor stroke patients with intracranial vessel occlusions (IVO) underwent mechanical thrombectomy (MT) versus those treated with intravenous thrombolysis alone (IVT). We retrospectively reviewed two large prospective stroke databases from two European centers searching for patients admitted with minor stroke (i.e. NIHSS Score░≤░5), baseline mRS░=░0 and occlusion of the M1–M2 segment of the middle cerebral artery (MCA). Groups receiving (A) IVT alone and (B) MT+/-IVT were compared. Primary outcome measures were MT safety, successful recanalization rate (mTICI 2b-3) and NIHSS shift (discharge NIHSS minus admission NIHSS); secondary outcomes included discharge rates and excellent outcome (mRS 0-1) at 3 months. Univariate and multivariate analyses were performed. Thirty-two patients were enrolled in Group B (19░MT alone; 13 MT░+░IVT) and 24 in Group A. Successful recanalization (mTICI 2b-3) was obtained in 100% of cases in Group B vs 38% in Group A. Symptomatic hemorrhagic transformation rate did not differ between the two groups. Multivariate analysis reported MT as the only predictor of early (<░12░h) favorable NIHSS shift and lower NIHSS at discharge. Moreover, discharge at home and excellent outcome at 3-month follow-up were statistically associated with MT. MT in patients with minor strokes and intracranial vessel occlusion (IVO) is safe and can determine a rapid improvement of NIHSS Score. MT seems also associated with a higher rate of patients discharged at home after hospitalization and better clinical outcome at 3-month follow-up. Larger randomized trials are warranted to confirm these results.
科研通智能强力驱动
Strongly Powered by AbleSci AI